Event and Time
Event Description
On 19 August 2022, ResApp Health Ltd ("ResApp") convened a meeting of members to consider a scheme of arrangement. However, just before the meeting, the company applied to postpone the meeting due to concerns about the adequacy of information disclosed to shareholders regarding the scheme and related financial matters.
Application and Claims
- ResApp's Claims:
- Sought court orders to postpone the scheme meeting scheduled for 19 August 2022. - Initially requested approval of a second explanatory statement and related communications with shareholders, but later focused solely on postponement.
- Concerns Raised:
- Inadequate disclosure of information surrounding a $680,000 bridging loan agreement with the acquirer, Pfizer Australia. - Notably, there were questions about the urgency of the capital needs and the potential risks to ResApp's intellectual property tied to the loan agreement.
Judicial Decisions
- The Court decided to postpone the meeting of members to a date to be fixed, reflecting the need for accurate and informative communication to shareholders prior to the meeting.
Dispute Points and Legal Basis
Dispute Points
- For ResApp:
- The financial urgency that necessitated the bridging loan shortly before the meeting was not sufficiently explained to shareholders. - Misstatements regarding terms of the bridging loan, particularly the notice periods related to defaults, raised concerns about transparency and shareholder understanding.
- For Pfizer Australia (implicitly):
- While Pfizer's role as the acquirer was critical, their obligation to adhere to their best and final offer was referenced. - Concerns from shareholders regarding the implications of securing a loan against ResApp's intellectual property were not fully addressed, bringing potential reputational and financial risk to the acquirer.